Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

cumberland pharmaceuticals inc - CPIX

CPIX

Close Chg Chg %
8.48 0.01 0.12%

Closed Market

8.49

+0.01 (0.12%)

Volume: 44.32K

Last Updated:

Oct 23, 2026, 4:00 PM EDT

Trade Now

Company Overview: cumberland pharmaceuticals inc - CPIX

CPIX Key Data

Open

$8.46

 Day Range

8.33 - 8.76

52 Week Range

1.85 - 9.28

 Market Cap

$122.41M

Shares Outstanding

14.98M

 Public Float

8.75M

Beta

0.04

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.73

Yield

0.00%

 Dividend

$1.50

EX-DIVIDEND DATE

Aug 3, 2026

 SHORT INTEREST

N/A

AVERAGE VOLUME

48.47K

  

CPIX Performance

1 Week
 
 18.25%
 
1 Month
 
 11.56%
 
3 Months
 
 28.44%
 
1 Year
 
 143.27%
 
5 Years
 
 215.61%
 

CPIX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About cumberland pharmaceuticals inc - CPIX

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. It operates through the following geographical segments: China, South Korea, Russia, Mexico, Australia, and Saudi Arabia. The firm products include Acetadote, Caldolor, Kristalose, Vaprisol, Talicia, Vibativ, Sancuso, Omeclamox, RediTrex, and Other. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

CPIX At a Glance

Cumberland Pharmaceuticals, Inc.
1600 West End Avenue
Nashville, Tennessee 37203
Phone 1-615-255-0068 Revenue 44.52M
Industry Pharmaceuticals: Major Net Income -2,836,128.00
Sector Health Technology 2025 Sales Growth 17.57%
Fiscal Year-end 12 / 2026 Employees 93
View SEC Filings

CPIX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.328
Price to Book Ratio 2.393
Price to Cash Flow Ratio 11.99
Enterprise Value to EBITDA 22.122
Enterprise Value to Sales 1.292
Total Debt to Enterprise Value 0.177

CPIX Efficiency

Revenue/Employee 478,725.065
Income Per Employee -30,496.00
Receivables Turnover 2.627
Total Asset Turnover 0.584

CPIX Liquidity

Current Ratio 1.009
Quick Ratio 0.839
Cash Ratio 0.311

CPIX Profitability

Gross Margin 75.714
Operating Margin -6.033
Pretax Margin -6.314
Net Margin -6.37
Return on Assets -3.722
Return on Equity -11.883
Return on Total Capital -8.089
Return on Invested Capital -7.817

CPIX Capital Structure

Total Debt to Total Equity 40.918
Total Debt to Total Capital 29.037
Total Debt to Total Assets 13.252
Long-Term Debt to Equity 39.038
Long-Term Debt to Total Capital 27.702
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cumberland Pharmaceuticals Inc - CPIX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
42.01M 39.55M 37.87M 44.52M
Sales Growth
+16.75% -5.85% -4.26% +17.57%
Cost of Goods Sold (COGS) incl D&A
14.45M 11.00M 11.49M 10.81M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
5.33M 5.77M 6.04M 5.29M
Depreciation
260.75K 1.01M 1.30M 1.25M
Amortization of Intangibles
5.07M 4.76M 4.75M 4.03M
COGS Growth
+7.67% -23.84% +4.42% -5.89%
Gross Income
27.56M 28.55M 26.38M 33.71M
Gross Income Growth
+22.14% +3.58% -7.60% +27.79%
Gross Profit Margin
+65.61% +72.18% +69.66% +75.71%
2022 2023 2024 2025 5-year trend
SG&A Expense
33.27M 35.03M 33.48M 36.39M
Research & Development
6.69M 5.83M 4.82M 5.57M
Other SG&A
26.58M 29.20M 28.66M 30.83M
SGA Growth
+5.98% +5.30% -4.43% +8.70%
Other Operating Expense
- - - -
-
Unusual Expense
- 2.25M (906.07K) 106.22K
EBIT after Unusual Expense
(5.70M) (8.73M) (6.20M) (2.79M)
Non Operating Income/Expense
709.74K 3.12M 334.44K 476.75K
Non-Operating Interest Income
98.41K 286.85K 334.44K 476.75K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
586.00K 667.86K 605.51K 495.99K
Interest Expense Growth
+497.76% +13.97% -9.34% -18.09%
Gross Interest Expense
586.00K 667.86K 605.51K 495.99K
Interest Capitalized
- - - -
-
Pretax Income
(5.58M) (6.28M) (6.47M) (2.81M)
Pretax Income Growth
-0.34% -12.61% -2.89% +56.53%
Pretax Margin
-13.29% -15.89% -17.08% -6.31%
Income Tax
68.85K 45.77K (22.67K) 40.26K
Income Tax - Current - Domestic
- - (22.67K) 40.26K
-
Income Tax - Current - Foreign
- - 68.85K 45.77K
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(5.65M) (6.33M) (6.44M) (2.86M)
Minority Interest Expense
(79.80K) (51.45K) 36.05K (28.58K)
Net Income
(5.57M) (6.28M) (6.48M) (2.84M)
Net Income Growth
-1.24% -12.73% -3.19% +56.23%
Net Margin Growth
-13.26% -15.88% -17.11% -6.37%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(5.57M) (6.28M) (6.48M) (2.84M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(5.57M) (6.28M) (6.48M) (2.84M)
EPS (Basic)
-0.3825 -0.4392 -0.4609 -0.1909
EPS (Basic) Growth
-62.56% -14.82% -4.94% +58.58%
Basic Shares Outstanding
14.56M 14.30M 14.06M 14.85M
EPS (Diluted)
-0.3825 -0.4392 -0.4609 -0.1909
EPS (Diluted) Growth
-62.56% -14.82% -4.94% +58.58%
Diluted Shares Outstanding
14.56M 14.30M 14.06M 14.85M
EBITDA
(376.82K) (710.85K) (1.06M) 2.60M
EBITDA Growth
+91.07% -88.64% -48.85% +345.74%
EBITDA Margin
-0.90% -1.80% -2.79% +5.84%

Insider Actions for Cumberland Pharmaceuticals Inc - CPIX

Date Name Shares Transaction Value
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,427 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.37 per share 19,210,438.99
Nov 3, 2025 Caroline R. Young Director 33,168 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.39 per share 112,439.52
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,544 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.28 per share 18,697,784.32
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,531 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.49 per share 19,894,853.19
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,518 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.51 per share 20,008,818.18
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,505 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.44 per share 19,609,737.20
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,492 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.62 per share 20,635,781.04
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,479 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.61 per share 20,578,729.19
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,466 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.52 per share 20,065,640.32
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,453 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.48 per share 19,837,576.44
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,440 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.49 per share 19,894,535.60
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,297 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.31 per share 18,867,983.07
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,414 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.35 per share 19,096,386.90
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,401 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.54 per share 20,179,419.54
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,388 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.59 per share 20,464,392.92
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,375 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.56 per share 20,293,335.00
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,362 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.63 per share 20,692,314.06
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,349 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.19 per share 18,184,113.31
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,336 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.14 per share 17,899,055.04
Nov 3, 2025 A. J. Kazimi Chairman and CEO; Director 5,700,323 Small acquisition under Rule 16a-6 Non-derivative transaction at $3.25 per share 18,526,049.75

Cumberland Pharmaceuticals Inc in the News